VALTRIX
Audit-aware AI for scientific screening and materials discovery. Built for reproducible candidate prioritization and benchmark-governed evidence reporting.
Flagship product: VALTRIX
Audit-aware AI for scientific screening.
AcuVizionAI builds reproducibility-first AI systems for scientific candidate prioritization. Its flagship platform, VALTRIX, helps R&D teams decide which materials or molecular candidates deserve costly validation.
Evidence
Matbench validated
Status
JARVIS prepared
Posture
Claim-safe
What this is
From prediction to auditable decision support
VALTRIX is not presented as a finished enterprise platform. It is a benchmark-validated, early-stage scientific ML engine for screening workflows, reproducible evaluation, and partner-ready technical review.
- Scientific screening and candidate prioritization
- Evidence chains and reproducibility controls
- Materials discovery and adjacent scientific R&D use cases
Claim boundary: Matbench is externally benchmark-validated. JARVIS is prepared for submission-style evaluation, with external public outcome pending.
Portfolio
One parent brand, one flagship product, and two supporting public-safe pages.
QuantX
A training-time meta-controller for curriculum and sampling decisions under audit constraints. The public page is patent-safe and intentionally non-enabling.
Investigation Copilot
A separate browser demo showing how risk scores and evidence can be turned into human-readable investigation narratives. Not the VALTRIX product.
Founder
Built by Kamran Soleimani
Kamran Soleimani is building AcuVizionAI in Belgium as an independent deeptech effort focused on audit-aware scientific ML, benchmark discipline, and reproducible decision infrastructure. Current work centers on VALTRIX for scientific screening and materials discovery.
Confidential R&D
Broader scientific discovery work
AcuVizionAI also maintains confidential exploratory work in computational drug discovery and other high-stakes scientific screening settings. Details are not publicly disclosed; high-level technical briefings can be shared selectively under NDA.
Partner, pilot, or technical review discussion
Open to strategic pilot partners, research collaborators, non-dilutive funding conversations, and deeptech investment discussions.
Email: [email protected]
Website: acuvizionai.com